• By ICR Secretariat
  • Posted Monday, September 5, 2022

ESC 2022: Bayer's Kerendia cuts risk of sudden cardiac death in patients with chronic kidney disease and type 2 diabetes

https://www.fiercepharma.com/pharma/esc-bayers-kerendia-can-cut-risk-sudden-cardiac-arrest-those-chronic-kidney-disease

While Bayer’s Kerendia can’t match the efficacy figures of other chronic kidney disease (CKD) drugs such as AstraZeneca’s Farxiga, the company believes there’s a market for it as a complementary treatment as it falls into a different drug class.